Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q1 2026 · 10-Q
Revenue—
Net Income-$10.79M-$10.79MN/M vs Q1 2025 EPS Diluted-$0.11-$0.11N/M vs Q1 2025 Operating Income-$11,436,000N/M Operating Cash Flow-$12,517,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$12,655,000N/M ended Mar 31, 2026 · filed May 15, 2026 · 45 d after period end